Description:
The current state of the art:
The primary objectives of wound healing include timely wound closure, prompt pain relief, reduced bacteria contamination, and an esthetically acceptable scar. The currently available wound dressings such as semiocclusive, hydrocolloids, and alginates, are used to heal wounds by creating a moist and clean environment to reduce bacteria colonization.
Problems with current state of art
However, if the wounds do not heal within 48 hours, they eventually become hosts to bacteria and get infected. While some antimicrobial dressing such as silver dressing has been developed, a wound dressing that can improve infection, induce wound closure, and reduce scare formation is lacking.
Advantages of our invention
The scientists at AU developed a novel method to reduce inflammation and promote wound healing by using a composition comprising the GILZ peptide fusion proteins. The GILZ peptide can be used to treat skin or mucosal wounds, acute, chronic or fibrotic wounds. In the mouse study, linking to a cell penetrating peptide, it induced wound healing in a non-healing wound, reduced scare formation (daily for at least six weeks), and reduced inflammation by blocking immune cells such as neutrophils infiltrating into the site.
AURI #2018-031
IP status: US Non-Provisional 16/541,252